Table 2. Spectrum of mutations in the ABL KD and SH3-SH2 domain of BCR/ABL gene according to the disease phase.
| CP | AP | BC | Total | PPhV2 score | |
|---|---|---|---|---|---|
| Patients with imatinib resistance | 76 | 9 | 9 | 94 | |
| Patients with mutations in BCR/ABL gene | 29 | 5 | 7 | 41 | |
| Patients with mutations in kinase domain | 37 | ||||
| P loop mutations | 16 | ||||
| M244V | 1 | 0 | 0 | 0.907 | |
| K247E | 1 | 0 | 0 | 0.814 | |
| G250E | 2 | 1 | 1 | 0.999 | |
| Y253F | 1 | 1 | 0 | 1 | |
| Y253H | 0 | 2 | 4 | 1 | |
| E255V | 1 | 0 | 0 | 0.951 | |
| del L248-K274* | 1 | 0 | 0 | ||
| Gatekeeper | 5 | ||||
| T315I | 3 | 0 | 1 | 1 | |
| F317L | 1 | 0 | 0 | 1 | |
| Catalytic domain | 11 | ||||
| M351T | 1 | 0 | 1 | 0.927 | |
| M351V | 1 | 0 | 0 | 0.927 | |
| E355G | 1 | 0 | 0 | 0.986 | |
| Ins GAA at 357th amino acid* | 1 | 0 | 0 | ||
| F359V | 1 | 0 | 0 | 0.989 | |
| F359I | 1 | 0 | 0 | 0.989 | |
| 35bp ins of intron 8 at exon 8–9 junction | 4 | 0 | 0 | ||
| Activation domain | 3 | ||||
| L387M | 1 | 1 | 0 | 0.969 | |
| H396R | 1 | 0 | 0 | 0.983 | |
| Patients with mutations in SH3-SH2 domain | 4 | ||||
| K84E* | 1 | 0 | 0 | 0.973 | |
| Y167H* | 1 | 0 | 0 | 0.677 | |
| del Exon 4 | 2 | 0 | 0 | ||
| Multiple mutations | 2 | ||||
| G250E-E255K | 1 | 0 | 0 | ||
| Ins CAGG* at 303th amino acid and F493L | 1 |
* Novel mutations detected